Author

J. Farhi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:proteomics· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

R. S. Lee· 3 shared A. H. Corbett· 2 shared A. L. Hong· 2 shared C. Y. Jones· 2 shared J. Spangle· 2 shared K. Sad· 2 shared R. B. Jones· 2 shared A. K. Verma· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. S. Lee

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Histone H3 E50K mutation confers oncogenic activity and supports an EMT phenotype

K. Sad, C. Y. Jones, D. V. Fawwal, E. J. Hill, K. Skinner, S. Lustenberger, R. S. Lee, S. R. Elayavalli, J. Farhi, L. D. Lemon, M. B. Fasken, A. L. Hong, S. A. Sloan, A. H. Corbett, J. M. Spangle

This paper shows that the H3E50K mutation in histone H3 promotes oncogenic activity by enhancing cell migration, invasion, and epithelial-mesenchymal transition.

bioRxiv · Oct 11, 2023 · PreprintCancer Biology

Dynamic in vivo mapping of the methylproteome using a chemoenzymatic approach

J. Farhi, B. Emenike, C. M. Beusch, R. S. Lee, R. B. Jones, A. K. Verma, C. Y. Jones, M. Foroozani, M. Reeves, K. Sad, K. K. Parwani, P. Bagchi, R. Deal, D. J. Katz, A. H. Corbett, , J. Spangle

This paper develops a chemoenzymatic method to map the methylproteome in vivo, identifying known and novel methylation sites across multiple organ systems in mice.

bioRxiv · Jul 22, 2022 · PreprintBiochemistry

Targeting MLL methyltransferases enhance the anti-tumor effects of PI3K inhibition in hormone receptor-positive breast cancer

R. B. Jones, J. Farhi, M. Adams, K. Parwani, M. Zecevic, G. Cooper, R. S. Lee, A. L. Hong, J. Spangle

This paper shows that combining PI3K and MLL1 inhibition enhances anti-tumor effects in HR+ breast cancer by disrupting a feedback loop between MLL1 and AKT.

bioRxiv · Oct 1, 2021Cancer Biology